Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | TEK | Q02763 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987880 | 0.77 | SCD (0.41) | MAPTEGLN1NR1I3 | |
| SCHEMBL1967033 | 0.77 | CYP19A1 (0.47) | MAPTCYP19A1NR1I3 | |
| SCHEMBL1969887 | 0.77 | GSK3B (0.36) | MAPTCYP19A1GSK3BROCK2PIM1 | |
| SCHEMBL1990584 | 0.75 | CD74 (0.41) | MAPTEGLN1 | |
| SCHEMBL1968025 | 0.73 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL1978454 | 0.71 | KDM4E (0.40) | MAPTEGLN1 | |
| SCHEMBL1985654 | 0.68 | EGLN1 (0.35) | EGLN1 | |
| SCHEMBL2181543 | 0.68 | ROCK2 (0.37) | GSK3BROCK2PIM1AURKBEGLN1 | |
| SCHEMBL1986297 | 0.67 | SCD (0.41) | EGLN1KDRTEKEPHB4 | |
| SCHEMBL1967187 | 0.67 | CYP19A1 (0.38) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2334666-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Canada Inc. (CA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025553-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | MAPT 2863/4885CYP19A1 264/4885GSK3B 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.